Physician profile
Deborah Gail Epling
NPI 1255705760
$2,105.37
in general payments reported to CMS, 2019-2025
22 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $418 · 2022: $352 · 2023: $342 · 2024: $615 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,335.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $873.40 | 2022-2025 | |
| Novo Nordisk INC | $237.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $142.31 | 2021-2025 | |
| Amgen INC. | $122.93 | 2021-2024 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.70 | 2021-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.56 | 2021 | |
| Glaxosmithkline, LLC. | $72.41 | 2022-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $61.44 | 2023-2024 | Jardiance, Zepbound, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $56.30 | 2022-2023 | |
| Astrazeneca Pharmaceuticals Lp | $53.66 | 2021-2025 | Breztri |
| Dexcom, INC. | $46.85 | 2021-2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $45.45 | 2021 | |
| Esperion Therapeutics, INC. | $35.09 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.95 | 2025 | Caplyta |
| Abbott Laboratories | $26.03 | 2023-2024 | Freestyle Libre 2 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $21.08 | 2025 | Flucelvax, Fluad |
| Axsome Therapeutics, INC. | $19.84 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $19.72 | 2023 | Invega Trinza, Invega Sustenna |
| Amarin Pharma, INC. | $18.51 | 2022 | |
| Indivior INC. | $16.56 | 2024 | Sublocade |
| Sumitomo Pharma America, INC. | $14.30 | 2024 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $13.18 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Epling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.